How many insider trades does FilingIQ track for ABOS?

FilingIQ tracks 140 Form 4 insider transactions for ABOS (Acumen Pharmaceuticals, Inc.), covering filings from Jul 6, 2021 onwards. 7 of those were filed in the last 90 days.

Are ABOS insiders net buyers or net sellers?

Across the full Form 4 history for ABOS, 9 transactions (6%) were open-market purchases and 62 (44%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ABOS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ABOS in?

Acumen Pharmaceuticals, Inc. (ABOS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $176.87M.

ABOS insider trading

NasdaqGS Healthcare

Acumen Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

140

Last 90 days

Buys / sells

6% / 44%

Market cap

$176.87M

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Company website: acumenpharm.com

ABOS insider activity at a glance

FilingIQ has scored 140 insider transactions for ABOS since Jul 6, 2021. The most recent filing in our index is dated Mar 16, 2026.

Across the full history, 9 open-market purchases and 62 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ABOS insider trades is 55.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ABOS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ABOS?: FilingIQ tracks 140 Form 4 insider transactions for ABOS (Acumen Pharmaceuticals, Inc.), covering filings from Jul 6, 2021 onwards. 7 of those were filed in the last 90 days.
Are ABOS insiders net buyers or net sellers?: Across the full Form 4 history for ABOS, 9 transactions (6%) were open-market purchases and 62 (44%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ABOS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ABOS in?: Acumen Pharmaceuticals, Inc. (ABOS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $176.87M.

Methodology & sources

Every ABOS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.